ArriVent BioPharma Inc
AVBP
NASDAQ
Biotechnology
$29.51
USD
-0.49 (-1.63%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.44B
Volume 439.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-113.84M
TTM
-7.8%
YoY
Operating Cash Flow
$-108.35M
TTM
-7.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.9 | 6.1 | 6.6 | 8.5 | 10.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 33.6 | 38.3 | 38.8 | 46.1 | 52.7 |
Operating Income | -33.6 | -38.3 | -38.8 | -46.1 | -52.7 |
EBITDA | -33.6 | -38.3 | -41.8 | -46.7 | -52.7 |
Other Income / Expense | 2.2 | 0.0 | 0.0 | 0.0 | 2.8 |
Total Other Income / Expense | 2.2 | 3.3 | 3.3 | 2.8 | 2.8 |
Income Before Income Taxes | -31.4 | -35.0 | -35.5 | -43.3 | -49.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 0.0 | -35.0 | -35.5 | -43.3 | 0.0 |
Consolidated Net Income / Loss | -31.4 | -35.0 | -35.5 | -43.3 | -49.9 |
Net Income Attributable to Common Shareholders | -31.4 | -35.0 | -35.5 | -43.3 | -49.9 |
Basic EPS | -$0.90 | -$0.83 | -$0.83 | -$0.96 | -$1.05 |
Diluted EPS | -$0.90 | -$0.83 | -$0.83 | -$0.96 | -$1.05 |
Basic Shares Outstanding | 35.0M | 41.9M | 43.0M | 45.1M | 47.6M |
Diluted Shares Outstanding | 35.0M | 41.9M | 43.0M | 45.1M | 47.6M |